Clinical significance of the nuclear receptor co-regulator DC-SCRIPT in breast cancer: an independent retrospective validation study
2010

The Role of DC-SCRIPT in Breast Cancer Prognosis

Sample size: 1505 publication 10 minutes Evidence: high

Author Information

Author(s): Sieuwerts Anieta M, Ansems Marleen, Look Maxime P, Span Paul N, de Weerd Vanja, van Galen Anne, Foekens John A, Adema Gosse J, Martens John WM

Primary Institution: Erasmus Medical Center

Hypothesis

DC-SCRIPT mRNA expression is a prognostic marker in breast cancer.

Conclusion

High levels of DC-SCRIPT are associated with reduced tumor aggressiveness, particularly in small tumors with high ESR1 or low ESR2 levels.

Supporting Evidence

  • DC-SCRIPT levels were positively associated with tumor grade and hormone receptor expression.
  • Higher DC-SCRIPT levels were linked to better disease-free survival.
  • DC-SCRIPT expression was most informative for small tumors and specific receptor statuses.

Takeaway

This study found that a substance called DC-SCRIPT can help predict how aggressive breast cancer will be, especially in smaller tumors.

Methodology

DC-SCRIPT mRNA levels were measured by real-time PCR in 1,505 primary invasive breast cancers and analyzed for associations with disease outcomes using Cox regression.

Potential Biases

Potential biases due to the non-randomized nature of the study.

Limitations

The study is retrospective and may not account for all confounding factors.

Participant Demographics

Female patients with primary operable breast cancer, aged from 1978 to 2000.

Statistical Information

P-Value

p<0.001

Confidence Interval

95% CI not specified

Statistical Significance

p<0.001

Digital Object Identifier (DOI)

10.1186/bcr2786

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication